Which has higher valuation and earnings, INSM or ARGX?

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 39.01 -$1.28B -$5.75 N/A argenex $4.25B 12.83 $1.29B $22.46 39.01

Is INSM or ARGX more profitable?

argenex has a net margin of 31.31% compared to Insmed's net margin of -144.44%. argenex's return on equity of 44.37% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% argenex 31.31% 44.37% 37.55%

Does the media refer more to INSM or ARGX?

In the previous week, Insmed had 8 more articles in the media than argenex. MarketBeat recorded 13 mentions for Insmed and 5 mentions for argenex. Insmed's average media sentiment score of 0.94 beat argenex's score of 0.65 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INSM or TAK?

Insmed currently has a consensus target price of $211.00, indicating a potential upside of 93.33%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 1 Sell rating(s) 0 Hold rating(s) 23 Buy rating(s) 1 Strong Buy rating(s) 2.96 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to INSM or TAK?

In the previous week, Insmed had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Insmed and 1 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 0.94 beat Takeda Pharmaceutical's score of -0.31 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INSM or RVMD?

In the previous week, Insmed had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 13 mentions for Insmed and 11 mentions for Revolution Medicines. Insmed's average media sentiment score of 0.94 beat Revolution Medicines' score of 0.63 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or INSM?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Insmed. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 13 mentions for Insmed. Teva Pharmaceutical Industries' average media sentiment score of 1.13 beat Insmed's score of 0.94 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 15 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ONC or INSM?

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 6.24 $286.93M $4.47 68.00 Insmed $606.42M 39.01 -$1.28B -$5.75 N/A

Is ONC or INSM more profitable?

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Insmed -144.44% -130.11% -51.57%

Does the media favor ONC or INSM?

In the previous week, Insmed had 5 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for Insmed and 8 mentions for BeOne Medicines. Insmed's average media sentiment score of 0.94 beat BeOne Medicines' score of 0.77 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Insmed (INSM) Competitors

$109.14 -6.47 (-5.60%)

Closing price 04:00 PM Eastern

Extended Trading

$108.56 -0.58 (-0.53%)

As of 07:46 PM Eastern

Compare

INSM vs. ARGX, TAK, RVMD, TEVA, and ONC

Should you buy Insmed stock or one of its competitors? MarketBeat compares Insmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insmed include argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Insmed compare to argenex?

Insmed (NASDAQ:INSM) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Insmed has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A
argenex	$4.25B	12.83	$1.29B	$22.46	39.01

In the previous week, Insmed had 8 more articles in the media than argenex. MarketBeat recorded 13 mentions for Insmed and 5 mentions for argenex. Insmed's average media sentiment score of 0.94 beat argenex's score of 0.65 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 31.31% compared to Insmed's net margin of -144.44%. argenex's return on equity of 44.37% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
argenex	31.31%	44.37%	37.55%

60.3% of argenex shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Insmed currently has a consensus price target of $211.00, indicating a potential upside of 93.33%. argenex has a consensus price target of $1,037.61, indicating a potential upside of 18.41%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to Takeda Pharmaceutical?

Insmed (NASDAQ:INSM) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Takeda Pharmaceutical has a net margin of 4.31% compared to Insmed's net margin of -144.44%. Takeda Pharmaceutical's return on equity of 11.20% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

Insmed has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A
Takeda Pharmaceutical	$28.32B	1.85	-$1.01B	$0.39	42.28

Insmed currently has a consensus target price of $211.00, indicating a potential upside of 93.33%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Insmed had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Insmed and 1 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 0.94 beat Takeda Pharmaceutical's score of -0.31 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Insmed beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Insmed (NASDAQ:INSM) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

94.3% of Revolution Medicines shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Revolution Medicines has lower revenue, but higher earnings than Insmed. Revolution Medicines is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A
Revolution Medicines	$11.58M	3,377.18	-$1.13B	-$7.07	N/A

In the previous week, Insmed had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 13 mentions for Insmed and 11 mentions for Revolution Medicines. Insmed's average media sentiment score of 0.94 beat Revolution Medicines' score of 0.63 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Revolution Medicines' return on equity of -83.22% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Revolution Medicines	N/A	-83.22%	-59.06%

Insmed currently has a consensus price target of $211.00, suggesting a potential upside of 93.33%. Revolution Medicines has a consensus price target of $144.00, suggesting a potential downside of 21.72%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Insmed has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Summary

Insmed and Revolution Medicines tied by winning 8 of the 16 factors compared between the two stocks.

How does Insmed compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, suggesting a potential upside of 29.94%. Insmed has a consensus target price of $211.00, suggesting a potential upside of 93.33%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Insmed's net margin of -144.44%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Insmed	-144.44%	-130.11%	-51.57%

Teva Pharmaceutical Industries has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.14	$1.41B	$1.33	24.17
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Insmed. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 13 mentions for Insmed. Teva Pharmaceutical Industries' average media sentiment score of 1.13 beat Insmed's score of 0.94 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	15 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Teva Pharmaceutical Industries beats Insmed on 11 of the 17 factors compared between the two stocks.

How does Insmed compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.24	$286.93M	$4.47	68.00
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Insmed	-144.44%	-130.11%	-51.57%

48.6% of BeOne Medicines shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BeOne Medicines presently has a consensus price target of $391.38, suggesting a potential upside of 28.76%. Insmed has a consensus price target of $211.00, suggesting a potential upside of 93.33%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

In the previous week, Insmed had 5 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for Insmed and 8 mentions for BeOne Medicines. Insmed's average media sentiment score of 0.94 beat BeOne Medicines' score of 0.77 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats Insmed on 9 of the 16 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.06B	$3.67B	$6.83B	$12.42B
Dividend Yield	N/A	2.19%	2.68%	8.01%
P/E Ratio	-18.98	21.03	27.15	24.29
Price / Sales	39.01	216.11	524.18	95.49
Price / Cash	N/A	61.98	29.22	49.39
Price / Book	31.54	8.49	10.75	6.29
Net Income	-$1.28B	$23.83M	$3.58B	$330.86M
7 Day Performance	-2.15%	-3.18%	-2.10%	-2.41%
1 Month Performance	11.54%	6.31%	3.32%	-0.64%
1 Year Performance	11.16%	52.74%	28.17%	20.09%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	4.1005 of 5 stars	$109.14 -5.6%	$211.00 +93.3%	+17.8%	$25.06B	$606.42M	N/A	1,664	Analyst Forecast Insider Trade
ARGX argenex	4.3754 of 5 stars	$916.80 -2.4%	$1,034.56 +12.8%	+56.7%	$58.44B	$4.25B	40.82	1,863
TAK Takeda Pharmaceutical	1.7945 of 5 stars	$16.91 +0.8%	N/A	+12.8%	$53.37B	$28.32B	43.35	47,000
RVMD Revolution Medicines	1.963 of 5 stars	$189.99 +0.4%	$142.33 -25.1%	+391.5%	$40.23B	$11.58M	N/A	250	Gap Down
TEVA Teva Pharmaceutical Industries	4.8032 of 5 stars	$35.29 +1.9%	$41.78 +18.4%	+100.3%	$39.83B	$17.26B	26.53	33,950	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors

INSM vs. ARGX, TAK, RVMD, TEVA, and ONC

How does Insmed compare to argenex?

Summary

How does Insmed compare to Takeda Pharmaceutical?

Summary

How does Insmed compare to Revolution Medicines?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Summary

How does Insmed compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Competitors

INSM vs. ARGX, TAK, RVMD, TEVA, and ONC

How does Insmed compare to argenex?

Which has more volatility & risk, INSM or ARGX?

Which has higher valuation and earnings, INSM or ARGX?

Does the media refer more to INSM or ARGX?

Is INSM or ARGX more profitable?

Do institutionals & insiders believe in INSM or ARGX?

Do analysts recommend INSM or ARGX?

Summary

How does Insmed compare to Takeda Pharmaceutical?

Is INSM or TAK more profitable?

Which has more risk & volatility, INSM or TAK?

Which has higher valuation & earnings, INSM or TAK?

Do analysts rate INSM or TAK?

Does the media refer more to INSM or TAK?

Do insiders and institutionals believe in INSM or TAK?

Summary

How does Insmed compare to Revolution Medicines?

Do institutionals & insiders hold more shares of INSM or RVMD?

Which has higher earnings & valuation, INSM or RVMD?

Does the media refer more to INSM or RVMD?

Is INSM or RVMD more profitable?

Do analysts prefer INSM or RVMD?

Which has more risk & volatility, INSM or RVMD?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Do analysts recommend TEVA or INSM?

Is TEVA or INSM more profitable?

Which has higher valuation and earnings, TEVA or INSM?

Do institutionals and insiders hold more shares of TEVA or INSM?

Which has more risk & volatility, TEVA or INSM?

Does the media favor TEVA or INSM?

Summary

How does Insmed compare to BeOne Medicines?

Which has preferable earnings and valuation, ONC or INSM?

Is ONC or INSM more profitable?

Do institutionals & insiders hold more shares of ONC or INSM?

Do analysts prefer ONC or INSM?

Which has more volatility and risk, ONC or INSM?

Does the media favor ONC or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools